In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von H Rachel Lagiakos und 17 weiteren Autor:innen. Beteiligte Einrichtung: Schrödinger Inc., New York, New York 10036, United States. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Neuroprotective Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Dual leucine zipper kinase (DLK), expressed primarily in neuronal cells, is a regulator of neuronal degeneration in response to cellular stress from chronic disease or neuronal injury. This makes it an attractive target for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, and neuronal injury, such as chemotherapy-induced peripheral neuropathy. Here, we describe the discovery of a potent, selective, brain-penetrant DLK inhibitor, KAI-11101 (59). Throughout the program's progression, medicinal chemistry challenges such as potency, hERG inhibition, CNS penetration, CYP3A time-dependent inhibition, and kinase selectivity were overcome through the implementation of cutting-edge in silico tools. KAI-11101 displayed an excellent in vitro safety profile and showed neuroprotective properties in an ex vivo axon fragmentation assay as well as dose-dependent activity in a mouse PD model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Schrödinger Inc., New York, New York 10036, United States.
- Schrödinger Inc., San Diego, California 92122, United States.
- Schrödinger Inc., Portland, Oregon 97204, United States.
- Viva Biotech, Shanghai 201203, China.
- Takeda California Inc., San Diego, California 92121, United States.
ORCID-Profile: H Rachel Lagiakos, Hideyuki Igawa, Eric Therrien, Morgan Lawrenz, Robert D Pelletier, Jeffrey A Bell, Robert J Skene, Zhe Nie
Zitieren
APA
Lagiakos, H. R., Zou, Y., Igawa, H., Therrien, E., Lawrenz, M., Kato, M., Svensson, M., Gray, F., Jensen, K., Dahlgren, M. K., Pelletier, R. D., Dingley, K., Bell, J. A., Liu, Z., Jiang, Y., Zhou, H., Skene, R. J., & Nie, Z. (2025). In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02074
Vancouver
Lagiakos HR, Zou Y, Igawa H, Therrien E, Lawrenz M, Kato M, et al. In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02074
BibTeX
@article{Lagiakos2025,
author = {Lagiakos, H Rachel and Zou, Yefen and Igawa, Hideyuki and Therrien, Eric and Lawrenz, Morgan and Kato, Mitsunori and Svensson, Mats and Gray, Felicia and Jensen, Kristian and Dahlgren, Markus K and Pelletier, Robert D and Dingley, Karen and Bell, Jeffrey A and Liu, Zhijian and Jiang, Yuansong and Zhou, Hua and Skene, Robert J and Nie, Zhe},
title = {In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02074}
}
EUVIMED